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Sirolimus increases transforming growth factor-b1 expression
and potentiates chronic cyclosporine nephrotoxicity.
Background. Sirolimus (SRL) is increasingly being used to
decrease cyclosporine (CsA) exposure. SRL is not known to be
nephrotoxic and has a mechanism of action distinct from CsA.
We investigated the effect of combining CsA and SRL on renal
structure and function and on transforming growth factor-b1
(TGF-b1) and extracellular matrix (ECM) proteins in a model
of chronic CsA nephrotoxicity.
Methods. Rats treated with vehicle, SRL 0.3 mg/kg/day, CsA
5 or 10 mg/kg/day, or CsA5+SRL were sacrificed at 7 or 28
days. Physiologic and histologic changes were studied in addi-
tion to TGF-b1 mRNA and protein expressions, and mRNA ex-
pression of plasminogen activator inhibitor-1 (PAI-1) and ECM
proteins biglycan and types I and IV collagen.
Results. While SRL alone did not alter renal function and
structure, it potentiated the nephrotoxic actions of CsA when
used in combination with low-dose CsA5 and resulted in signifi-
cant changes similar to high-dose CsA10. In addition, SRL alone
increased TGF-b1 by 44% to 49% (P < 0.05 vs. VH). When used
in combination with low-dose CsA5, SRL potentiated TGF-b1
mRNA and protein by 121% and 176%, respectively (P < 0.05
vs. VH and CsA5), to levels achieved with high-dose CsA10.
The expression of the ECM proteins followed that of TGF-b1;
a similar effect was observed with PAI-1, suggesting a decrease
in ECM degradation.
Conclusion. Because SRL augments nephrotoxicity, caution
should be exercised when it is used in combination with CsA.
More studies are needed to determine the long-term clinical
impact of SRL on nephrotoxicity and allograft function.
Cyclosporine (CsA) has played an important role
in improving renal allograft survival [1]. However, the
major side effect of long-term CsA administration con-
tinues to be chronic nephrotoxicity [2]. Chronic nephro-
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toxicity contributes, to a large extent, to the development
and progression of chronic allograft nephropathy, an un-
explained lesion that can result in renal allograft fail-
ure [3]. Chronic CsA nephrotoxicity is characterized by
a decrease in glomerular filtration rate (GFR), afferent
arteriolopathy, and striped tubulointerstitial fibrosis [4].
Our previous studies using an experimental model of
chronic CsA nephrotoxicity have shown that transform-
ing growth factor-b1 (TGF-b1) is involved in the fibrosis
of this model by increasing extracellular matrix (ECM)
synthesis, and decreasing ECM degradation through in-
creasing the activity of plasminogen activator inhibitor-1
(PAI-1) [5–8]. Apoptosis plays a role in this model where
the loss of cells may prevent the ability of the kidney to
remodel effectively [9]. Sirolimus (SRL) is increasingly
being used as a maintenance immunosuppressive agent
with designs to decrease or eliminate CsA exposure [10].
SRL binds to FK-binding protein and inhibits the mam-
malian target of rapamycin (mTOR), a critical regulator
of cell growth and survival [11]. The immunosuppressive
actions of SRL are synergistic to those of CsA because
SRL influences biochemical events later in the T-cell cy-
cle [12]. Furthermore, SRL inhibits growth factor–driven
proliferation of smooth muscle cells, fibroblasts, and en-
dothelial cells, and reduces intimal hyperplasia in models
of vascular injury [13–18]. These properties on vascular
changes have led many to believe that SRL may be a
beneficial addition in chronic lesions of the allograft.
SRL by itself does not seem to cause significant nephro-
toxicity in most animal and human studies [19–23]. When
used in the absence of CsA, SRL is able to spare glomeru-
lar filtration rate (GFR) in renal allografts; however,
when combined with CsA, serum creatinine levels often
increase [10, 24–26]. In addition, even when subthera-
peutic doses of CsA and SRL are used in combination, a
synergistic effect on the development of chronic nephro-
toxicity becomes evident in the rat [27]. Recent studies
have also shown that SRL given around the time of renal
injury can augment injury and delay repair [27–31]. The
mechanism is thought to be a result of enhanced necrosis,
increased apoptosis, and decreased proliferation of renal
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tubular epithelial cells [29]. Clinically, this translates into
delayed graft function after kidney transplantation in ad-
dition to a newly described lesion of cast nephropathy in
renal allografts of patients treated with SRL [30, 31]. It is
to be noted that, in addition to ischemia reperfusion in-
jury, CsA is probably also involved in promoting an early
acute injury after transplantation by causing potent renal
vasoconstriction.
There is also recent evidence to suggest that SRL
can independently increase TGF-b1 expression in lym-
phocytes and in renal proximal tubular epithelial cells
[32–34]. Moreover, patients treated with SRL have an
enhanced production of TGF-b1 and type III colla-
gen early after kidney transplantation [35, 36]. Because
TGF-b possesses profound immunomodulatory and anti-
inflammatory functions in the appropriate cytokine
milieu, this can explain some of the immunoregulatory
properties of CsA and SRL. However, it remains unclear
if the enhanced production of a fibrogenic cytokine such
as TGF-b will carry long-term consequences on the kid-
ney, particularly in recipients treated with a CsA-based
regimen. In this paper, we used low doses of CsA in order
to examine the impact of SRL coadministration on kid-
ney structure and function in experimental chronic CsA
nephrotoxicity and on the expression of TGF-b1, PAI-1,
and some ECM proteins in the kidney.
METHODS
Experimental design
Adult male Sprague-Dawley rats (Charles River,
Wilmington, MA, USA) weighing 325 to 350 g were
housed in a temperature- and light-controlled environ-
ment. They received a low-salt diet (0.05% sodium;
Teklad Premier, Madison, WI, USA) and were allowed
free access to tap water. Animals were pair-fed and
weighed daily. After one week on a low-salt diet, weight-
matched animals were assigned to one of five groups of
12 animals. Six animals in each group were sacrificed at
7 days (Groups A to E), and 6 were sacrificed at 28 days
(Groups F to J). The experimental groups (N = 6/group)
were: Groups A and F, vehicle (VH) control; Groups B
and G, SRL 0.3 mg/kg/day; Groups C and H, CsA 5 mg/
kg/day (CsA5); Groups D and I, CsA 5 mg/kg/day and
SRL 0.3 mg/kg/day (CsA5+SRL); and Groups E and J,
CsA 10 mg/kg/day (CsA10). Systolic blood pressure was
measured by tail plethysmography (Natsume Seisakusho
Co. Ltd., Tokyo, Japan), and 24-hour urine samples were
collected in metabolic cages (Nalge Company, Rochester,
NY, USA). The following day, rats were anesthetized
with intraperitoneal ketamine, the abdomen was opened
through a midline incision, and the aorta was retrogradely
cannulated below the renal arteries with an 18-gauge nee-
dle. With the aorta occluded by ligation above the renal
arteries, and the renal veins opened by a small incision
for outflow, the kidneys were perfused with 20 mL of cold
heparinized saline. The left kidney was removed and pro-
cessed for light microscopy. After removing the right kid-
ney, the cortex was dissected from the medulla, and the
cortex was processed for RNA and protein analysis. Af-
ter the experiment, the animals were euthanized by deep
anesthesia with ketamine followed by exsanguination.
Drugs
CsA (Novartis Research Institute, East Hanover, NJ,
USA) was diluted in olive oil and administered subcu-
taneously (sc) at a dose of 5 or 10 mg/kg/day. The ve-
hicle group received olive oil at 1 mL/kg/day sc. SRL,
obtained from Wyeth-Ayerst Research (Princeton, NJ,
USA), was dissolved using a dilution of Tween 80 (10%),
N-N-dimethylacetamide (20%) and polyethylene glycol
400 (70%), and was given to animals sc at 0.3 mg/kg/day.
Functional studies
Blood was collected from the jugular vein in plastic
syringes transferred to metal-free tubes and chilled on
ice. Plasma was harvested immediately by centrifugation
at 4◦C and stored at −70◦C until determined. Urinary
and plasma creatinine, blood urea nitrogen, and glucose
levels were measured by a Cobas autoanalyzer (Roche
Diagnostics, Hoffman-La Roche, Inc., Nutley, NJ, USA).
CsA blood level was measured by a fluorescence polar-
ization immunoassay (Abbott Diagnostics, Abbott Park,
IL, USA). SRL blood level was measured by a micropar-
ticle enzyme immunoassay (Abbott Diagnostics).
Histology
Tissue was fixed in 10% buffered formalin and in
Methyl Carnoy’s solution, and then embedded in paraf-
fin. Sections 2 to 4 l thick were stained with periodic
acid-Schiff reagent and trichrome stain, and evaluated
by light microscopy by an observer masked to the treat-
ment groups for tubular injury, interstitial fibrosis, and af-
ferent arteriolopathy. Findings ascribed to tubular injury
included cellular and intercellular vacuolization, tubular
collapse, and tubular distention.
Interstitial fibrosis consisted of matrix expansion with
tubular distortion and collapse and basement membrane
thickening. Arteriolopathy was characterized by expan-
sion of the cell cytoplasm of terminal arteriolar smooth
muscle cells by eosinophilic, granular material. A color-
image analyzer (Nikon E400; Nikon, Inc., Tokyo, Japan;
Pixera Professional digital camera, Macintosh Power-
book G3, NIH Image vs. 1.5) was used for semiquan-
titative scoring. The extent of tubular injury in cortical
tubules was graded using the following score: 0 = no
tubular injury; 0.5 = <5% of tubules injured; 1 = 5%
to 20%; 1.5 = 21% to 35%; 2 = 36% to 50%; 2.5 = 51%
to 65%; and 3 = >65%. Interstitial fibrosis was estimated
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by counting the percentage of injured areas per fields of
cortex and medulla with a minimum of 30 fields (magni-
fication, ×200) reviewed using the following score: 0 =
normal interstitium; 0.5 = <5% of areas injured; 1 = 5%
to 20%; 1.5 = 21% to 35%; 2 = 36% to 50%; 2.5 = 51% to
65%; 3 = >65%. Afferent arteriolopathy was estimated
by counting the percentage of juxtaglomerular afferent
arterioles with arteriolopathy per total afferent arterioles
available for examination (magnification, ×200), with a
minimum of 100 glomeruli per biopsy assessed. The fol-
lowing score was used: 0 = no arterioles injured; 0.5 =
<15% of arterioles injured; 1 = 15% to 30%; 1.5 = 31%
to 45%; 2 = 46% to 60%; 2.5 = 61% to 75%; 3 = >75%.
Northern blot analysis
Renal tissue was finely minced with a razor blade on
ice then homogenized in TRIzol reagent (Gibco BRL,
Grand Island, NY, USA). RNA extraction was performed
according to the manufacturer’s protocol. After resus-
pension in Tris-EDTA buffer, RNA concentrations were
determined using spectrophotometric readings at ab-
sorbance 290 nm. Thirty micrograms of RNA were elec-
trophoresed in each lane in 0.9% agarose gels containing
2.2 mol/L formaldehyde and 0.2 mol/L MOPS (pH 7.0)
and transferred to a nylon membrane (ICN Biomedicals,
Costa Mesa, CA, USA) overnight by capillary blotting.
Nucleic acids were crosslinked by ultraviolet irradiation
(Stratagene, La Jolla, CA, USA). The membranes were
prehybridized for 2 hours at 42◦C with 50% formamide,
10% Denhardt’s solution, 0.1% sodium dodecyl sulfate
(SDS), 5× standard saline citrate (SSC), and 200 lg/mL
denatured salmon sperm DNA. Membranes were then
hybridized at 42◦C for 18 hours with cDNA probes la-
beled with 32P-dCTP by random oligonucleotide prim-
ing (Boehringer Mannheim, Mannheim, Germany). The
blots were washed in 2× SSC, 0.1% SDS at room tem-
perature for 15 minutes, and in 0.1× SSC, 0.1% SDS
at 50◦C for 15 minutes. Films were exposed at −70◦C
for different time periods to ensure linearity of den-
sitometric values and exposure time. Autoradiographs
were scanned on an imaging densitometer (GS-700; Bio-
Rad Laboratories, Hercules, CA, USA). The density of
bands for the glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) mRNA was used to control for differ-
ences in the total amount of RNA loaded onto each gel
line. For quantitative purposes, the values were divided
by the density of bands for GAPDH in the same lane. The
cDNA probes used for Northern were: a mouse TGF-b1
cDNA probe (plasmid MUI5); a rat PAI-1 cDNA probe
(plasmid pBluescript SK(−)); a human biglycan cDNA
probe (plasmid P16); a rat procollagen a1 cDNA (plasmid
pa1R1); a rat collagen IV cDNA probe (plasmid pCIV-
1-PE16) (American Type Culture Collection, Manassas,
VA, USA); and a rat GAPDH cDNA probe (plasmid
pBluescript KS II).
Table 1. Physiologic changes in the experimental groups
Body Systolic Blood Urea plasma Glucose
weight plasma BP creatinine nitrogen level
g mm Hg mg/dL mg/dL ng/mL
7 days
VH 325 ± 8 125 ± 8 0.58 ± 0.01 14 ± 1 148 ± 13
SRL 310 ± 7 120 ± 7 0.59 ± 0.01 16 ± 2 133 ± 10
CsA5 322 ± 6 121 ± 8 0.58 ± 0.01 18 ± 3 171 ± 14
CsA5+ 311 ± 6 122 ± 7 0.65 ± 0.04 21 ± 3 141 ± 15
SRL
CsA10 313 ± 6 128 ± 9 0.60 ± 0.01 24 ± 3 199 ± 19
28 days
VH 402 ± 10 129 ± 10 0.60 ± 0.01 15 ± 1 117 ± 2
SRL 377 ± 12 125 ± 8 0.61 ± 0.02 21 ± 2 102 ± 5
CsA5 385 ± 9 125 ± 7 0.69 ± 0.01 22 ± 2 172 ± 13
CsA5+ 361 ± 10 121 ± 10 0.95 ± 0.05a,b,c 38 ± 5a,b,c 187 ± 36
SRL
CsA10 380 ± 10 122 ± 6 0.86 ± 0.02a,b,c 38 ± 4a,b,c 222 ± 43a,b
Abbreviations are: VH, vehicle placebo; CsA5, cyclosporine 5 mg/kg/day; CsA10,
CsA 10 mg/kg/day; SRL, sirolimus 0.3 mg/kg/day; BP, blood pressure.
Data are mean ± SEM of 6 animals. aP < 0.05 vs. VH; bP < 0.05 vs. SRL; cP < 0.05
vs. CsA5.
Immunoassay
Frozen (−70◦C) kidney tissue sections embedded in
Tissue-Tek O.C.T. compound (Miles, Inc. Diagnostics
Division, Elkhart, IN, USA) were processed for pro-
tein extraction. Tissue was thawed at 4◦C in 5 mL ly-
sis buffer (GITC/BME), then rinsed 3 times in 5 mL
cold 4◦C phosphate-buffered saline (PBS), pH 7.4. Pro-
tein extracts were prepared by homogenizing kidney
tissue in 1 mL cold PBS containing 0.05% Tween 20
(PBS-T) with a glass tissue homogenizer (Kontes Glass,
Vineland, NJ, USA). The homogenate was centrifuged
at 4◦C for 15 minutes at 15,000g, and the supernatant
was collected and then centrifuged to remove cellular
debris. Protein concentration in the supernatant was de-
termined using the Micro BCA (bicinchoninic acid) as-
say (Pierce, Rockford, IL, USA). Latent TGF-b1 was
activated to immunoreactive TGF-b1 and was detected
by a commercially available TGF-b1–specific sandwich
enzyme-linked immunosorbent assay (ELISA) (Quan-
tikine; R&D Systems, Minneapolis, MN, USA). The man-
ufacturer’s recommendations were followed for sample
activation, reagent preparation, assay procedure, and cal-
culation of results.
Statistical analysis
Results were expressed as mean ± standard error.
All statistical analyses were calculated with SYSTAT
for Macintosh, version 5.2 (SYSTAT, Inc., Chicago, IL,
USA). Comparisons between groups were done using
analysis of variance (Tukey-Kramer analysis followed by
Tukey’s test). A P value less than 0.05 was considered
statistically significant.
RESULTS
Physiologic studies
Values for weight gain, systolic blood pressure, plasma
creatinine, blood urea nitrogen, and plasma glucose levels
are summarized in Table 1. Weight gain was progressive
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Table 2. Histologic semiquantitative scoring
Tubular injury Interstitial fibrosis Arteriolopathy
0–3+ 0–3+ 0–3+
7 days
VH 0 ± 0 0 ± 0 0 ± 0
SRL 0 ± 0 0 ± 0 0 ± 0
CsA5 0.1 ± 0.1 0 ± 0 0 ± 0
CsA5+SRL 0.3 ± 0.2 0 ± 0 0.2 ± 0.1
CsA10 0.3 ± 0.2 0 ± 0 0.3 ± 0.1
28 days
VH 0.1 ± 0.1 0.1 ± 0.1 0.1 ± 0.1
SRL 0.3 ± 0.1 0.4 ± 0.2 0.2 ± 0.1
CsA5 0.5 ± 0.1 0.5 ± 0.1 0.4 ± 0.1
CsA5+SRL 1.4 ± 0.2a,b,c 1.8 ± 0.2a,b,c 1.9 ± 0.1a,b,c
CsA10 1.3 ± 0.2a,b,c 1.6 ± 0.3a,b,c 1.7 ± 0.2a,b,c
Abbreviations are: VH, vehicle placebo; CsA5, cyclosporine 5 mg/kg/day;
CsA10, cyclosporine 10 mg/kg/day; SRL, sirolimus 0.3 mg/kg/day.
Data are mean ± SEM of 6 animals. aP < 0.05 vs. VH; bP < 0.05 vs. SRL;
cP < 0.05 vs. CsA5.
VH SRL
CsA5+SRLCsA5
CsA10 X 200
Fig. 1. Tubulointerstitial changes. Representative photomicrographs
showing the renal cortex of a salt-depleted rat given vehicle (VH),
sirolimus 0.3 mg/kg/day (SRL), cyclosporine 5 mg/kg/day (CsA5), cy-
closporine 5 mg/kg/day + SRL (CsA5+SRL), or cyclosporine 10 mg/
kg/day (CsA10) and sacrificed at 28 days. Rats treated with either VH
or SRL alone had a normal renal histology. Rats treated with low-dose
CsA5 had minimal tubulointerstitial changes that were not significant.
However, rats treated with either higher dose CsA10, or with combi-
nation of low-dose CsA5+SRL showed similar significant tubulointer-
stitial changes characterized by striped interstitial fibrosis and tubular
atrophy (Trichrome, magnification ×200).
in all treatment groups. Although SRL-treated rats did
not gain weight at the same rate as others, there were
no significant differences in body weight between the
groups for the entire study period. Systolic blood pres-
sure remained similar between groups, and hypertension
was not observed in any group. Similar to VH, treatment
with SRL did not affect kidney function. In addition,
VH SRL
CsA5+SRLCsA5
CsA10 X 400
Fig. 2. Arteriolopathy changes. Representative photomicrographs
showing the renal cortex of a salt-depleted rat given vehicle (VH),
sirolimus 0.3 mg/kg/day (SRL), cyclosporine 5 mg/kg/day (CsA5), cy-
closporine 5 mg/kg/day + SRL (CsA5+SRL), or cyclosporine 10 mg/
kg/day (CsA10) and sacrificed at 28 days. Rats treated with either VH
or SRL did not have any arteriolopathy. Rats treated with low-dose
CsA5 had only minimal arteriolopathy changes that were not signifi-
cant. However, rats treated with higher dose CsA10, or with combina-
tion of low-dose CsA5+SRL, showed similar significant homogenous
accumulation of eosinophilic material within the smooth muscle cells
of afferent arterioles (Trichrome, magnification ×400).
administration of low doses of CsA5 did not result in
significant changes in plasma creatinine and blood urea
nitrogen compared with VH- or SRL-treated rats. How-
ever, as expected, relatively large doses of CsA10 sig-
nificantly increased plasma creatinine and blood urea
nitrogen levels at 28 days (P < 0.05 vs. VH and SRL).
When SRL was given with low-dose CsA5 in the CsA5+
SRL group, significant increases in plasma creatinine and
blood urea nitrogen levels were observed at 28 days ver-
sus CsA5-treated rats (P < 0.05), and the changes were
similar to CsA10-treated rats.
At the currently utilized doses and route of adminis-
tration, SRL and CsA5 did not result in changes in the
plasma glucose levels. However, when CsA10 was ad-
ministered, a significant increase in plasma glucose was
observed at 28 days (P < 0.05 vs. VH).
Histologic changes
Scores for the histologic changes observed are summa-
rized in Table 2. Representative photomicrographs are
shown in Figures 1 and 2. VH-treated rats had normal kid-
ney histology. Treatment with low-dose CsA 5 mg/kg/day
resulted in mild histologic changes with scores for
tubular injury, interstitial fibrosis, and arteriolopathy of
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Fig. 3. Mean area under the plasma concentration curve (AUC) and
blood trough levels of cyclosporine (CsA) with and without sirolimus
(SRL) administration. Rats were administered CsA at a dose of either
5 or 10 mg/kg/day subcutaneously, or CsA 5 mg/kg/day with SRL at a
dose of 0.3 mg/kg/day subcutaneously. CsA blood trough levels were
obtained (A), in addition to mean AUC (B).
0.5 ± 0.1, 0.5 ± 0.1, and 0.4 ± 0.1, respectively, that did not
reach statistically significance compared to VH-treated
rats. Similar not significant changes were also noted in
SRL-treated rats. Treatment with either SRL or with low-
dose CsA5 did not result in any significant tubular in-
jury, interstitial fibrosis, or arteriolopathy. By contrast, at
28 days, kidneys of rats treated with CsA10 developed
tubular atrophy, striped interstitial fibrosis, and renal
vascular lesions characterized by hypertrophied smooth
muscle cells of afferent arterioles with characteristic gran-
ular eosinophilic transformation. On the other hand, the
addition of SRL to low-dose CsA5 resulted in significant
histologic changes of tubular injury, interstitial fibrosis,
and arteriolopathy, similar to the changes seen with the
higher dose of CsA10.
Pharmacokinetic studies
Figure 3 summarizes the results of CsA pharmacoki-
netics with and without SRL administration after 7 days
of drug administration. CsA blood trough levels (ng/mL)
were similar in rats treated with CsA5 (1010 ± 90) and
with CsA5+SRL (1050±150). The area under the plasma
concentration time curve (AUC0-24) was also similar in
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Fig. 4. Mean area under the plasma concentration curve (AUC) and
blood trough levels of sirolimus (SRL) with and without cyclosporine
(CsA) administration. Rats were administered SRL at a dose of 0.3 mg/
kg/day subcutaneously alone or in combination with CsA 5 mg subcu-
taneously. SRL blood trough levels were obtained (A) in addition to
mean AUC (B).
the CsA5 and CsA5+SRL-treated rats (23 ± 3 and 29 ±
4 mg.h/L, respectively). These results indicate the ab-
sence of significant pharmacokinetic interactions related
to CsA when CsA and SRL are coadministered subcu-
taneously. On the other hand, as expected, the higher
CsA10 doses resulted in significantly higher (P < 0.05)
CsA blood trough levels (2150 ± 230) and AUC0-24 (41 ±
5). The pharmacokinetics of SRL after 7 days with and
without CsA administration are summarized in Figure 4.
Although SRL blood trough levels (ng/mL) were slightly
higher in the CsA5+SRL group (12 ± 2) than the SRL
group (9 ± 1), the difference did not achieve statistical sig-
nificance. The AUC0-24 of SRL was also not statistically
different between the SRL and CsA5+SRL groups; the
values were 105 ± 11 and 121 ± 18 lg.h/L, respectively.
These results further indicate the absence of significant
pharmacokinetic interactions related to SRL when CsA
and SRL are coadministered subcutaneously.
Expression of TGF-b1
Compared to VH rats, SRL administration resulted in
significantly higher TGF-b1 mRNA and protein levels
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Fig. 5. Northern blot expression of transforming growth factor-b1
(TGF-b1) mRNA. Total RNA was isolated from the whole cortex and
was hybridized with a cDNA probe to TGF-b1. Results of densitomet-
ric analysis after correcting for GAPDH mRNA for 7 days (A) and
28 days (B) are shown. A Northern blot representative (28 days) is also
shown (C). ∗P < 0.05 vs. vehicle (VH); #P < 0.05 vs. SRL; †P < 0.05 vs.
CsA5.
(P < 0.05) in the kidney. At 7 and 28 days, SRL alone
increased TGFb1 mRNA by 50% and 44%, respectively,
and protein levels by 34% and 49%, respectively. The ef-
fect of low-dose CsA5 on TGF-b1 expression was similar
to SRL early at 7 days (53% for mRNA and 70% for pro-
tein, P < 0.05 vs. VH), but was significantly higher than
SRL at 28 days (78% for mRNA and 140% for protein,
P < 0.05 vs. VH and SRL). The higher dose of CsA10 re-
sulted in even more marked increases of 82% to 125% for
mRNA and 74% to 190% for protein (7 to 28 days, P <
0.05 vs. VH); these changes were significantly higher than
either SRL alone or CsA5 (P < 0.05 at 28 days). How-
ever, when SRL was added to low-dose CsA5, the result
was a potentiation in TGF-b1 mRNA and protein expres-
sion in the kidney to the levels observed with the higher
doses of CsA10. These values were significantly higher
than either SRL alone or CsA5 (P < 0.05 at 28 days).
TGF-b1 mRNA expression in the kidney in the
VH
SRL
CsA5
CsA5+SRL
CsA10
A
*#
*#
*
*
0 0.2 0.4 0.6 0.8 1
7 days
VH
SRL
CsA5
CsA5+SRL
CsA10
B
*#†
*#†
*#
*
0 0.2 0.4 0.6 0.8 1
28 days
pg per 0.1 µg of total protein
Fig. 6. Enzyme-linked immunosorbent assay (ELISA) expression of
transforming growth factor-b1 (TGF-b1) protein. TGF-b1 protein ex-
pression was determined by ELISA from whole cortex homogenates for
both 7 days (A) and 28 days (B). ∗P < 0.05 vs. VH; #P < 0.05 vs. SRL;
†P < 0.05 vs. CsA5. Abbreviations are: CsA5, cyclosporine 5 mg/kg/day;
CsA10, cyclosporine 10 mg/kg/day; SRL, sirolimus 0.3 mg/kg/day; VH,
vehicle.
CsA5+SRL group was 79% to 121% higher, while that
of TGF-b1 protein was 76% to 176% higher when com-
pared to VH-treated rats. The results for TGF-b1 mRNA
expression are shown in Figure 5, and those for TGF-b1
protein expression are shown in Figure 6.
Expression of PAI-1
The renal expression of PAI-1, a plasmin protease in-
hibitor that blocks ECM degradation and that is directly
stimulated by TGF-b , is shown in Figure 7. PAI-1 mRNA
expression paralleled that of TGF-b1 with significant in-
creases in PAI-1 expression with CsA5 and more marked
changes with the higher dose of CsA10 (P < 0.05 vs. VH
groups). Treatment with SRL alone increased PAI-1 ex-
pression at 7 and 28 days to levels that remained lower
than CsA5, but which were significantly higher than VH-
treated rats (P < 0.05). The combination of CsA5+SRL
resulted in significant changes in PAI-1 expression that
equated CsA10 and that were significantly higher than
either SRL or CsA5 treatment at both time points (P <
0.05 vs. SRL and vs. CsA5).
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Fig. 7. Northern blot expression of plasminogen activator inhibitor-1
(PAI-1) mRNA. Total RNA was isolated from the whole cortex and
was hybridized with a cDNA probe to PAI-1. Results of densitometric
analysis after correcting for GAPDH mRNA for 7 days (A) and 28 days
(B) are shown. A Northern blot representative (28 days) is also shown
(C). ∗P < 0.05 vs. VH; #P < 0.05 vs. SRL; †P < 0.05 vs. CsA5. Ab-
breviations are: CsA5, cyclosporine 5 mg/kg/day; CsA10, cyclosporine
10 mg/kg/day; SRL, sirolimus 0.3 mg/kg/day; VH, vehicle.
Expression of ECM proteins
The renal expression of biglycan and of types I and IV
collagen by Northern blot analysis is shown in Figure 8.
These ECM proteins are directly stimulated by TGF-b ;
their expression followed that of TGF-b1 and progres-
sively increased in the CsA groups (P < 0.05 vs.VH),
suggesting active ECM synthesis, with the changes being
more significant with the higher doses of CsA10. Of note
is that SRL increased the mRNA expression of biglycan
at 28 days and of type I collagen at 7 and 28 days, but
had no effect on type IV collagen at both time points.
The increases with SRL were not as pronounced as with
CsA5 or CsA10 and were not accompanied by any signif-
icant histologic changes (see above). However, the addi-
tion of SRL to low-dose CsA5 resulted in increases in the
mRNA expression of the above ECM proteins, although,
unlike what was observed with TGF-b1 and PAI-1, the
changes did not reach the CsA10 levels. These changes
were mostly seen at 28 days and were most pronounced
with type I collagen and to a lesser extent with biglycan
(P < 0.05 vs. CsA5) and type IV collagen (P < 0.05 vs.
SRL).
DISCUSSION
SRL has potent immunosuppressive effects that are
distinct from calcineurin inhibitors [10–12]. SRL was
shown to reduce the incidence of acute rejection in re-
nal transplant recipients and to achieve powerful im-
munosuppression in several models of transplantation.
Because SRL is not known to be nephrotoxic, a poten-
tial approach to decreasing chronic CsA nephrotoxicity
is to utilize a lower dose of CsA with the synergistic im-
munosuppressant SRL. Some of the clinical studies on
the use of SRL in the setting of CsA minimization have
shown an improved serum creatinine and GFR with rel-
atively short-term follow-ups [21–23, 37–39]. However,
the effect of this drug combination on long-term graft
survival remains unknown. In addition, there are no de-
tailed chronic nephrotoxicity studies on the combination
of CsA and SRL.
We utilized an animal model of chronic CsA nephro-
toxicity in order to study the effect of low-dose CsA ad-
ministered in combination with SRL on renal structure
and function. In this study, we were able to show that
SRL was not nephrotoxic when used alone. On the other
hand, when CsA was used in doses previously shown to
cause nephrotoxicity, significant changes in the kidney
were seen, including a decrease in GFR, afferent arte-
riolopathy, and striped tubulointerstitial fibrosis. These
characteristic CsA-induced changes were not observed
when lower doses of CsA (half the dose that produces
nephrotoxicity) were administered. However, when com-
bined with SRL, low-dose CsA resulted in changes in re-
nal structure and function similar to the changes observed
with full-dose CsA. In other words, SRL potentiated the
known nephrotoxic potential of CsA in this model. These
results confirm previous observations in which CsA and
SRL were synergistic in producing nephrotoxicity [27].
In addition, a number of clinical studies noted that the
use of SRL with CsA was associated with a rise in serum
creatinine and a worsening in GFR. These results were
initially unexpected from a drug that has antiproliferative
effects. SRL inhibits the proliferation of smooth muscle
cells, fibroblasts, and endothelial cells [13, 14]. SRL also
reduces intimal hyperplasia in immune and nonimmune
models of vascular injury, and halts or partially regresses
established cardiac allograft disease in rodents and aortic
allograft vascular disease in primates [14–18]. The prop-
erties of SRL on the vasculature were hypothesized to
be beneficial in the setting of chronic CsA nephrotoxic-
ity, and it is based on those observations that SRL was
thought to allow the minimization of CsA exposure, and
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Fig. 8. Northern blot expression of extracel-
lular matrix (ECM) proteins. Total RNA was
isolated from the whole cortex and was hy-
bridized with a cDNA probe to biglycan,
type I collagen, and type IV collagen. Re-
sults of densitometric analysis after correct-
ing for GAPDH mRNA for 7 and 28 days
(A) are shown. A Northern blot represen-
tative (28 days) is also shown (B). ∗P <
0.05 vs. VH; #P < 0.05 vs. SRL; †P <
0.05 vs. CsA5. Abbreviations are: CsA5, cy-
closporine 5 mg/kg/day; CsA10, cyclosporine
10 mg/kg/day; SRL, sirolimus 0.3 mg/kg/day;
VH, vehicle.
VH SRL CsA5 CsA5
+SRL
CsA10
Biglycan
Type IV collagen
Type I collagen
GAPDH
B Kb
−2.6
−5.7
−4.7
−6.5
−1.3
thus, nephrotoxicity. However, in the setting of experi-
mental chronic CsA nephrotoxicity, the expected bene-
ficial effect of SRL on the vasculature was not observed
because the addition of SRL to low-dose CsA potenti-
ated the arteriolopathy and resulted in scores similar to
high-dose CsA that are known to cause significant arte-
riolopathy.
One possible explanation for the effect of SRL on en-
hancing CsA nephrotoxicity is a pharmacokinetic inter-
action leading to increased CsA drug concentrations and,
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as a result, more CsA renal exposure [25, 40, 41]. When
used clinically, SRL is administered 4 hours after CsA
in an attempt to reduce the interaction between the two
drugs. This is particularly true when both drugs are given
orally, but is not observed when they are coadministered
subcutaneously [25, 27, 40, 41]. In this study where both
drugs were delivered subcutaneously, we show that CsA
blood trough levels and AUC were unaffected by SRL.
However, a pharmacokinetic interaction that may result
in increased CsA concentrations within the kidney tissue
cannot be ruled out.
Another possible explanation is that SRL increases
the production of the fibrogenic cytokine TGF-b . In this
study, the administration of SRL alone, without CsA, was
associated with inducing TGF-b1 production. TGF-b has
potent immunosuppressive properties and may be a prin-
cipal mediator of the immunosuppressive effects of SRL
and calcineurin inhibitors. In the early phases of immune
recognition, TGF-b may be beneficial in inhibiting im-
mune activation and may have a significant effect on in-
ducing tolerance [42]. However, the impact of a sustained
up-regulation of TGF-b1 in the kidney remains a serious
concern, especially when there is abundant data linking
excessive TGF-b production with the development of fi-
brosis [43]. In this study, while therapy with SRL alone
for 28 days did not result in significant fibrosis, a longer
follow-up may have been needed. These findings also con-
firm previous observations, in which SRL addition in vitro
was found to induce TGF-b production in lymphocytes,
and more recently, in proximal renal tubular cells. There
is yet another property that is common to both SRL and
TGF-b , and that is inhibition of cell proliferation [13–18].
The antiproliferative effect of SRL has been attributed
to the inhibition of signaling events involved in cell cycle
progression. However, it seems reasonable to attribute
some of this effect to the antiproliferative properties of
TGF-b . The other major concern is that the use of SRL
in combination with low doses of CsA was associated
in this model with a significant augmentation of TGF-
b1 production. The net result was a TGF-b1 expression
that was similar to what was observed with full doses of
CsA, an effect previously demonstrated in this model.
Concomitant with the increase in TGF-b1 was also an
up-regulation in the expression of biglycan and collagens
to levels, thus indicating active ECM synthesis. In addi-
tion, PAI-1 was similarly increased, suggesting a decrease
in ECM degradation.
In other words, the effect of SRL on low-dose CsA
was to restore all the components in the machinery of
fibrosis previously observed with full-dose CsA. These
findings are supported by another study, in which SRL
increased TGF-b expression in leukocytes and in which
such increases were augmented significantly when com-
bined with CsA [32]. A more recent study in 31 patients
with biopsy-confirmed chronic allograft nephropathy
showed that the addition of SRL after CsA dose reduc-
tion was not associated with a reduction in TGF-b1 or
collagen type III expression in the renal allograft [36].
In another study in kidney transplant recipients main-
tained on a CsA-based regimen, fine needle aspirates of
the kidney obtained 7 days after transplantation showed a
significant up-regulation of TGF-b1 synthesis in the SRL
group compared with the mycophenolate mofetil (MMF)
group [35].
We have previously shown that apoptosis plays an im-
portant role in the development of chronic CsA nephro-
toxicity [9]. CsA, by inducing the expression of a number
of proapoptotic genes, impairs the ability of the kidney to
remodel effectively in response to injury. A similar effect
on apoptosis was also observed with SRL [29]. Whether
this effect is mediated through TGF-b , a known inducer
of apoptosis, remains unclear [44]. In the setting of exper-
imental renal injury, SRL inhibits the proliferation and
increases the apoptosis of renal tubular epithelial cells
[29]. Furthermore, SRL appears to induce renal injury in
experimental renal models of salt depletion and ischemia
[20, 29]. As a result, the combined use of SRL and CsA
may augment ischemia-induced renal injury and may in-
hibit tissue repair. This effect is involved in prolonging
the recovery from delayed graft function and in the de-
velopment of a cast nephropathy lesion [30, 31]. It is to
be noted that the risk of enhanced injury and decreased
repair may be relevant, not only in the immediate post-
transplant period, but also in later events causing renal
allograft injury, such as acute rejection or urinary tract
obstruction.
In de novo renal allograft recipients, new trials have
shown improvements in renal function in transplant re-
cipients taking SRL after CsA elimination [22, 23]. Other
studies have successfully adopted a similar scale approach
in recipients with established chronic allograft nephropa-
thy [45]. These results, in addition to the above evidence,
suggest that future regimens that involve the introduction
of SRL to CsA-treated patients should eliminate rather
than reduce CsA, thus avoiding any potential interfer-
ence between these agents. In addition, patients on a SRL
plus CsA regimen should have more prolonged follow-
ups in order to assess the impact of this drug combination
on long-term renal allograft function and structure.
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